In the International stroke trial the group that received heparin had a significant 0.9% reduction in risk of recurrent stroke within 14 days. This was however counter balanced by a significant 0.8% increase in haemorrhagic stroke.
Trials involving low-molecular weight heparins, nadroparin and danaparoid have not convincingly shown benefit of these therapies.
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.